Urinary Disorder TRIZ Cases

Adjusted migalastat dosing intervals help Fabry patients with severe renal impairment or dialysis maintain α-Gal A activity and reduce renal substrate buildup.

Dual HIF-2α and VEGF-pathway blockade addresses refractory RCC after prior therapy, reducing tumor volume and extending progression-free survival.

Targeting ASNS and related metabolic pathways disrupts glutamine use and fatty acid synthesis to slow renal and liver cyst growth in ADPKD.

Oral migalastat stabilizes renal function in Fabry patients with renal impairment while lowering lyso-Gb3 and increasing α-Gal A activity.

A multi-herb composition targets qi deficiency, blood stasis, and fluid retention to improve cardiorenal syndrome and heart failure outcomes.

Alpha blockers and androgen inhibitors can cause temporary relief or sexual side effects; mixed Curcumae and Syzygii extracts target BPH pathways.

Migalastat stabilizes mutant α-Gal A and renal function in Fabry patients with mild to moderate renal impairment.

This case uses 100–150 mg migalastat every other day to stabilize renal function and increase α-Gal A activity in Fabry patients.

A multi-herb composition shrinks kidney cysts and improves renal function in polycystic kidney disease patients.

Chromanol derivatives improve renal function by targeting oxidative damage in aging disorders.

Administers fixed-ratio ambrisentan and tadalafil to reduce pulmonary arterial pressure while minimizing adverse effects from higher individual dosages.

Selective STAT3 inhibitors block fibroblast activation pathways, reducing extracellular matrix deposition and halting renal fibrosis progression.

Combines urinary acidifiers with crystallization inhibitors to synergistically delay calcium phosphate precipitation.

Engineered factor H variant extends serum half-life to sustain complement regulation and eliminate frequent intravenous dosing requirements.

Encapsulating sulforaphane in acacia gum prevents recurrence after surgery while avoiding side effects.

An oligonucleotide binds to the human nSR100 gene to inhibit its expression.

Elephantorrhiza extracts inhibit the 5α-reductase enzyme to reduce prostate size without sexual dysfunction side effects.

Replacing non-renewable bark harvesting with Prunus domestica stem cuttings to sustain supply while maintaining extract quality.

Salt hydrate forms of A1 adenosine receptor antagonists resolve low bioavailability to enhance glomerular filtration rate and reduce serum creatinine.

p21 mRNA-targeting DNAzymes resolve non-specific effects by selectively eliminating senescent cells through targeted mRNA cleavage.

Standardized trisodium citrate replacement fluids eliminate custom compounding complexity while maintaining metabolic control and dialyzer patency.

Quisqualis indica extract reduces prostate weight and dihydrotestosterone levels without toxic side effects.

Biodegradable scaffolds deliver aryl hydrocarbon receptor effectors to regenerate bladder tissue, restoring capacity without intestinal segment complications.

Sida rhombifolia extract reduces 5-alpha reductase activity and dihydrotestosterone production to treat benign prostatic hyperplasia.

A nutritional supplement combines pumpkin seed extract, L-citrulline, vitamin D3, and prebiotic fiber to strengthen pelvic floor muscles.

Merging RAAS inhibitors and omega-3 polyunsaturated fatty acids delays terminal renal failure in Alport syndrome.

A triple layer tablet uses swellable outer layers to form gelled barriers around an inner immediate-release core.

Achillea millefolium essential oil mitigates cadmium-induced renal toxicity by reducing oxidative stress and inflammation markers.

A peony stamen and dodder composite treats chronic kidney disease through desensitization, saline impregnation, and ultrasonic extraction.

Segmented enteric coating using Eudragit S100 and L100-55 prevents gastric dissolution, resolving bioavailability limits to achieve stable therapeutic effects.

An RNA vaccine composition encodes multiple prostate antigens to stimulate adaptive immunity.

A microfluidic bioreactor device controls chemical and mechanical stimuli through permeable membranes.

A pharmaceutical composition combining palmitoylethanolamide and Phyllanthus niruri extract to reduce pain and inflammation.

Canavalia ensiformis supplement prevents protamine sulfate induced cystitis by neutralizing oxidative stress and maintaining bladder compliance.

Microcrystalline cellulose and colloidal silicon dioxide resolve cohesion issues in pharmaceutical blends, enabling stable tablet manufacturing.

Oral vadadustat modulates hypoxia-inducible factor prolyl hydroxylase to stimulate endogenous erythropoietin production.

Cranberry extract proanthocyanidins block bacterial adhesion to urinary tract epithelial cells.